Targeting tumor-associated macrophages in pancreatic cancer Authors: Yuxi Long, Luoyingzi Xie, Fuming Xie, Xianxing Wang, Huaizhi Wang, Tian Yang, Lei Cai Published: 2026 ABSTRACT Tumor-associated macrophages (TAMs) constitute a major immune cell population within the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment and play pivotal roles in tumor progression, immune evasion, stromal remodeling, and therapeutic resistance. Classically activated M1 macrophages generally exert anti-tumor effects, while alternatively activated M2-like macrophages predominantly facilitate tumor growth and immunosuppression. In this review, we aim to systematically summarize the current understanding of TAM polarization, subtype-specific functions, and emerging macrophage-targeted therapeutic strategies in PDAC, with particular emphasis on translational advances and existing clinical challenges. A comprehensive literature review was conducted focusing on TAM biology, key signaling pathways involved in macrophage polarization, preclinical therapeutic approaches, and currently available clinical trial evidence in PDAC. Multiple signaling pathways, including colony-stimulating factor 1/colony stimulating factor 1 receptor, janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3), phosphatidylinositol 3-kinase -γ, cluster of differentiation 40, and toll-like receptor-associated pathways, have been implicated in TAM polarization in PDAC. Current therapeutic strategies mainly involve promoting M1 polarization, depleting M2-like macrophages, and reprogramming immunosuppressive TAMs toward anti-tumor phenotypes. Promising therapeutic agents include selicrelumab, ruxolitinib, colony stimulating factor 1 receptor inhibitors, spleen tyrosine kinase inhibitors, and Toll-like receptor agonists. In addition, neoadjuvant FOLFIRINOX chemotherapy may enhance M1-like macrophage infiltration through immunogenic cell death and TME remodeling. However, several strategies remain largely at the preclinical stage. Direct evidence supporting certain subtype-specific mechanisms, particularly those involving M2b macrophages in PDAC, remains limited. Overall, TAM-targeted therapy represents a promising immunotherapeutic strategy for PDAC. Future clinical translation will depend on improved target specificity, biomarker-guided patient stratification, and rational combination therapeutic approaches. Introduction Pancreatic cancer (PC) is a highly deadly malignancy, with only 20% of patients diagnosed at an early, resectable stage, resulting in poor overall survival.1 While advancements in combination chemotherapy regimens have improved treatment outcomes, second-line options remain limited. Additionally, recurrence is frequent, highlighting the need for novel therapeutic approaches. Emerging research emphasizes the role of immune dysfunction in the tumor microenvironment (TME), prompting increased exploration of immunotherapeutic strategies to enhance patient survival rates.2, 3, 4, 5, 6 The goal of immunotherapy is to target cells in the TME, a key determinant of tumor growth, recurrence, and therapeutic responsiveness. In pancreatic ductal adenocarcinoma (PDAC), the TME comprises cancer cells, the extracellular matrix (ECM), and stromal components, including tumor-associated macrophages (TAMs), CD4+/CD8+ T cells, myeloid-derived suppressor cells (MDSCs), and pancreatic stellate cells (PSCs).7, 8, 9 Intratumoral immune cells are classified into two functional subtypes: anti-tumor and tumor-promoting.10 The anti-tumor immune compartment contains effector T lymphocytes (CD8+ cytotoxic T cells and effector CD4+ T cells), natural killer (NK) cells, dendritic cells (DCs), and M1-polarized macrophages. By contrast, the pro-tumorigenic cellular population includes M2-polarized macrophages, regulatory T cells, MDSCs, N2-polarized neutrophils, natural killer T type 2 cells, and type II innate lymphoid cells (Fig. 1).11, 12, 13, 14Fig. 1Macrophage subtype interactions and immune regulation mechanisms in the pancreatic cancer tumor microenvironment. (Created in BioRender.Long,Y[2026] https://BioRender.com/armpm26).Abbreviations: Arg1, arginase 1; CCL, (C-C motif) ligand; DC, dendritic cell; EMT, epithelial-mesenchymal transition; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ, interferon-γ; IL, interleukin; ILC2, lymphoid cell; LPS, lipopolysaccharides; MDSC, myeloid-derived suppressor cell; PanIN, pancreatic intraepithelial neoplasia; PC, pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma; TGF-β, transforming growth factor-β; TME, tumor microenvironment; TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor. Macrophage subtype interactions and immune regulation mechanisms in the pancreatic cancer tumor microenvironment. (Created in BioRender.Long,Y[2026] https://BioRender.com/armpm26). Abbreviations: Arg1, arginase 1; CCL, (C-C motif) ligand; DC, dendritic cell; EMT, epithelial-mesenchymal transition; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ, interferon-γ; IL, interleukin; ILC2, lymphoid cell; LPS, lipopolysaccharides; MDSC, myeloid-derived suppressor cell; PanIN, pancreatic intraepithelial neoplasia; PC, pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma; TGF-β, transforming growth factor-β; TME, tumor microenvironment; TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor. Macrophages, which play a key role in both innate and adaptive immunity, are more densely present in the mesenchyme than in the intraepithelial regions of PC. M1 macrophages are known for eliminating tumor cells and producing pro-inflammatory cytokines that activate inflammatory T cells, while M2 macrophages promote tumor progression by secreting oncogenic factors, supporting cancer stem cells, promoting angiogenesis, and fostering an immune-evasive microenvironment.15,16 TAMs, which comprise about 11% of the cellular makeup in PDAC, can significantly facilitate tumor progression by inhibiting immune surveillance and promoting angiogenesis. Following neoadjuvant therapy in PC, the number of macrophages increased, particularly M1 macrophages, which are associated with better patient outcomes.17, 18, 19 Moreover, neoadjuvant intervention was found to reduce the population of M2 macrophages, a cell type closely linked to inferior overall survival in individuals with PDAC.18,20 In this review, we systematically describe the pivotal roles of macrophage subtypes in PC, providing a comprehensive overview of their origins, classifications, and distinct functions. Additionally, we explore the promising therapeutic avenues associated with each subtype. Here, we aim to deepen our understanding of these macrophage subtypes in PC and assess their potential as therapeutic targets. Macrophage classification and functions in PC The origin of macrophages Macrophage differentiation and biological functions exhibit strong context dependence, differing by the specific tissues and organs where these cells are present. Tissue-resident macrophages (TRMs) are derived during embryonic development from the yolk sac, fetal liver, or bone marrow.21 By contrast, macrophages that infiltrate damaged or infected tissues are generated via the differentiation of hematopoietic stem cells within the bone marrow. At injury sites, macrophages primarily differentiate from monocytes, where they can phagocytose pathogens and damaged cells while releasing pro-inflammatory factors, thereby playing a critical role in the immune response.22 Recent studies have shown that TAMs originate from two primary sources, the first of which involves monocytes generated from myeloid progenitor cells in the bone marrow. These cells leave the peripheral circulation and subsequently mature into macrophages within target tissues. The other source arises from early embryonic development, with macrophages differentiating in tissues to become TRMs.23 These TRMs are abundant in various cancer tissues, contributing to tumor progression and metastasis by remodeling the ECM and interacting with fibroblasts to enhance collagen and ECM-related gene expression.21 In PC, TRMs that originate from embryonic progenitors proliferate in situ and promote fibrosis by facilitating interstitial connective tissue formation, thereby aiding in cancer initiation and progression.21 Macrophage types in the TME Naïve macrophages (M0 macrophages) Naïve macrophages (M0) represent an undifferentiated, non-polarized population that can undergo polarization toward either the M1 or M2 phenotype, both of which contribute significantly to TAM network formation within the tumor immune microenvironment. Compared with healthy pancreatic tissue, PC lesions exhibit a marked elevation in the total number of macrophages, including the M0, M1, and M2 subsets. M0 macrophages interact extensively with diverse immune cell populations, with a high M0 abundance accompanied by clearly decreased numbers of CD8+ T lymphocytes, resting mast cells, quiescent DCs, and M1 macrophages.24 Increased M0 macrophage infiltration in PC correlates with diminished patient survival outcomes. Specifically, PC patients who display an M0 macrophage proportion of over 9.8% of the total macrophage pool have demonstrated markedly poorer prognostic outcomes.25 M0 macrophages can differentiate into M1 macrophages when activated by lipopolysaccharide and T helper 1 cell (Th1) cytokines, such as interferon-γ (IFN-γ) and tumor necrosis factor α (TNF-α), while they can differentiate into M2 macrophages when stimulated by interleukin (IL)-4, IL-13, IL-10, or IL-33.26 Transforming growth factor β inducible protein (TGFBI) can inhibit M0-to-M2 macrophage polarization and M0-driven PC growth, while enhancing anti-tumor activity.21 Through these mechanisms, targeting TGFBI in M0 macrophages has therefore shown potential as a therapeutic strategy for PC. In PC, the macrophage polarization status exhibits remarkable plasticity. It is tightly modulated by the equilibrium between TNF-α signaling, which suppresses the transcriptional program of M2-type macrophages, and additional regulatory factors, which can promote the phenotypic transition from M1 to M2 polarization (Fig. 2).15Fig. 2Macrophage polarization and functional diversity in tumor progression. (Created in BioRender. Long, Y [2026] https://BioRender.com/p5lmcs6).Abbreviations: CCL, (C-C motif) ligand; IL, interleukin; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α. Macrophage polarization and functional diversity in tumor progression. (Created in BioRender. Long, Y [2026] https://BioRender.com/p5lmcs6). Abbreviations: CCL, (C-C motif) ligand; IL, interleukin; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α. M1-polarized macrophages M1 macrophages are characterized by high levels of IL-12 and IL-23 and low levels of IL-1026. These cells generate functional effector molecules, including reactive oxygen species, nitrogen intermediates, and pro-inflammatory cytokines, such as interleukin-1 β (IL-1β), tumor necrosis factor α (TNF-α), and interleukin-6 (IL-6). Such bioactive factors are indispensable for triggering Th1-type immune responses and mediating protective immunity against intracellular pathogens, as well as fighting malignant tumors. In the initial phase of neoplastic lesion development, both acinar cells and M1 macrophages release multiple regulatory factors, among which is acinar-derived granulocyte-macrophage colony-stimulating factor, which further stabilizes and enhances the M1 macrophage polarization phenotype.15,26 M1 macrophages are more effective in early cancer development and exhibit more potent anti-tumor effects than M2 macrophages, which dominate the later stages.15 As crucial components of the Th1 response, M1 macrophages can eliminate microorganisms and tumor cells, while promoting inflammatory T cell activation through pro-inflammatory cytokine secretion.27,28 M2-polarized macrophages After M2 macrophages are stimulated by T helper 2 cell (Th2)-related cytokines, such as IL-4 and IL-13, they can secrete various anti-inflammatory mediators, including IL-1 receptor antagonist (IL-1ra) and IL-10.26,29 TGF-β1 plays a pivotal role in M2 macrophage polarization, thereby contributing to an immune-evasive TME.30,31 M2 macrophages exhibit elevated expression levels of various microRNAs (miRNAs), such as miR-146, miR-155, miR-221, miR-320, and miR-382. Specifically, miR-155 and miR-221 can facilitate angiogenesis in an E2F2-dependent manner.32 Within the TME, infiltrating monocytes, M-MDSCs, and TRMs differentiate into TAMs, which then promote tumor growth, angiogenesis, and metastasis.33 TAMs in PC are primarily polarized toward the M2 phenotype, contributing to poor prognosis by inhibiting M1 chemokine expression and fostering a TME that favors immune-escape. In PC, CD163 expression levels exceed those of major histocompatibility complex II (HLA-DR), highlighting the dominance of the M2 macrophage phenotype over M1. M2-like TAMs can directly drive tumor growth via the secretion of oncogenic factors, as well as indirectly by nurturing cancer stem cells or promoting angiogenesis.34,35 During the transition from acinar-to-ductal metaplasia (ADM) to pancreatic intraepithelial neoplasia, the macrophage populations shift, with M1 macrophages predominating in ADM regions and M2 macrophage numbers increasing in pancreatic intraepithelial neoplasias.36, 37, 38 M2 macrophages, which also highly express CHIL3 (YM1), can release various immunomodulatory cytokines, including IL-10 and TGF-β1. These factors effectively inhibit T cell immune responses and drive Th2 polarization, ultimately fostering an immunosuppressive TME.15 Furthermore, M2 macrophages exhibit high surface expression levels of the characteristic receptor CD206, with conformational alterations of this receptor effectively inducing M2 macrophage phenotypic reprogramming toward the M1 subtype.39 Higher densities of M2 macrophages in PC are correlated with advanced disease progression, increased metastasis, and diminished survival rates.40 Subtypes of M2-polarized macrophages M2 macrophages can be further classified into three subgroups, including M2a, M2b, and M2c, by their response to stimuli in vitro. Although these subpopulations are induced by distinct stimuli and exhibit phenotypic and functional differences, all M2 macrophage subpopulations share a typical cytokine expression profile characterized by high IL-10 levels and low IL-12 levels.35,41 In a previous study, Anders et al. reported that the functional phenotyping of these three M2-polarized macrophage subtypes was conducted using a systems biology approach. Their findings revealed that the M2a subtype exhibited high CD86 and HLA-DR expression, with low CD163 expression; the M2b subtype showed low expression of both HLA-DR and CD163, and the M2c subtype displayed high CD163 expression but low CD86 and HLA-DR expression.42 The study further delineated the specific characteristics of each subtype: M2a macrophages, triggered by IL-4 or IL-13, express IL-1ra and IL-1 receptor type II, as well as secrete cytokines, such as IL-10, TGF-β, C-C motif chemokine ligand 17 (CCL17), and CCL22, which enhance macrophage endocytosis to promote cell growth and tissue repair; M2b macrophages, induced by immune complexes, toll-like receptor (TLR) ligands, or IL-1β, secrete cytokines, including TNF-α, IL-6, IL-1, high levels of IL-10, and low levels of IL-12, thereby modulating the immune response; and M2c macrophages, stimulated by IL-10, TGFβ1, and glucocorticoids, generate pentraxin-3, TGF-β, and IL-10, crucial for tissue remodeling processes.28,29,43,44 Notably, while in vitro studies have established the functional characteristics of the M2a, M2b, and M2c macrophage subsets,35,45 their specific spatial distribution, dynamic evolution, and independent functional contributions within the PDAC TME remain inadequately defined.46,47 In particular, direct experimental evidence supporting a distinct pro-tumorigenic role for M2b macrophages in PC is currently limited.46,47 Therefore, the discussion of M2b-targeted therapeutic strategies in PC should currently be regarded as hypothesis-generating rather than evidence-based46, 47, 48 (Table 1).Table 1Macrophage subtype specific markers, functional roles in tumor immunity, and associated therapeutic targets.Table 1Macrophage subtypeSpecific markerFunctional roles in tumor immunityTherapeutic targetsReferencesM0Polarized into M1 or M2, promotes tumor growth24M1 (Anti-tumor or Classically Activated)IL-12, IL-23, TNF-α, iNOSPromotes Th1 responses, kills tumor cellsProduce pro-inflammatory cytokines (e.g., IL-12, TNF-α)Promote anti-tumor immunity by enhancing T-cell responsesInhibit tumor growth and proliferationCD40 agonists, IFN-γ15,26,40,43,49M2 (Pro-tumor or Alternatively Activated)IL-10, TGF-β, CD163, CD206, Arg1, YM1Promotes tumor growth, immune suppressionSecrete anti-inflammatory cytokines (e.g., IL-10, TGF-β)Suppress immune responses, facilitating tumor growthPromote tissue remodeling, angiogenesis, and metastasisCSF-1R Inhibitors, STAT3 inhibitors15,34,35,39,43,46,47M2aIL-4, CCL17, Arg1Induced by IL-4 and IL-13Promotes tissue repair and fibrosisEnhances immune suppression via TGF-β productionCSF-1R Inhibitors: Reduce macrophage recruitment (e.g., pexidartinib)IL-4/IL-13 Blockade: Prevents M2a differentiation28,35,43,46M2bTNF-α, IL-1β, CCL1Induced by immune complexes and TLR ligandsRegulates immune responses by balancing pro- and anti-inflammatory signalsCan suppress adaptive immunityTLR Modulation: Alters macrophage responsesCCL1 Inhibitors: Reduce immune suppression35,43M2cTGF-β1, IL-10, CD163, TGF-βInduced by IL-10 and glucocorticoidsExhibits strong immunosuppressive functionsPromotes tumor immune evasion and survivalTGF-β inhibitors28,42,50Abbreviations: Arg1, Arginase 1; CCL, (C-C motif) ligand; CSF-1R, colony stimulating factor 1 receptor; IFN-γ, interferon-γ; IL, interleukin; iNOS, inducible nitric oxide synthase; TGF-β, transforming growth factor-β; TLR, toll-like receptor; TNF-α, tumor necrosis factor-α. Table 1Macrophage subtype specific markers, functional roles in tumor immunity, and associated therapeutic targets.Table 1Macrophage subtypeSpecific markerFunctional roles in tumor immunityTherapeutic targetsReferencesM0Polarized into M1 or M2, promotes tumor growth24M1 (Anti-tumor or Classically Activated)IL-12, IL-23, TNF-α, iNOSPromotes Th1 responses, kills tumor cellsProduce pro-inflammatory cytokines (e.g., IL-12, TNF-α)Promote anti-tumor immunity by enhancing T-cell responsesInhibit tumor growth and proliferationCD40 agonists, IFN-γ15,26,40,43,49M2 (Pro-tumor or Alternatively Activated)IL-10, TGF-β, CD163, CD206, Arg1, YM1Promotes tumor growth, immune suppressionSecrete anti-inflammatory cytokines (e.g., IL-10, TGF-β)Suppress immune responses, facilitating tumor growthPromote tissue remodeling, angiogenesis, and metastasisCSF-1R Inhibitors, STAT3 inhibitors15,34,35,39,43,46,47M2aIL-4, CCL17, Arg1Induced by IL-4 and IL-13Promotes tissue repair and fibrosisEnhances immune suppression via TGF-β productionCSF-1R Inhibitors: Reduce macrophage recruitment (e.g., pexidartinib)IL-4/IL-13 Blockade: Prevents M2a differentiation28,35,43,46M2bTNF-α, IL-1β, CCL1Induced by immune complexes and TLR ligandsRegulates immune responses by balancing pro- and anti-inflammatory signalsCan suppress adaptive immunityTLR Modulation: Alters macrophage responsesCCL1 Inhibitors: Reduce immune suppression35,43M2cTGF-β1, IL-10, CD163, TGF-βInduced by IL-10 and glucocorticoidsExhibits strong immunosuppressive functionsPromotes tumor immune evasion and survivalTGF-β inhibitors28,42,50Abbreviations: Arg1, Arginase 1; CCL, (C-C motif) ligand; CSF-1R, colony stimulating factor 1 receptor; IFN-γ, interferon-γ; IL, interleukin; iNOS, inducible nitric oxide synthase; TGF-β, transforming growth factor-β; TLR, toll-like receptor; TNF-α, tumor necrosis factor-α. Macrophage subtype specific markers, functional roles in tumor immunity, and associated therapeutic targets. Abbreviations: Arg1, Arginase 1; CCL, (C-C motif) ligand; CSF-1R, colony stimulating factor 1 receptor; IFN-γ, interferon-γ; IL, interleukin; iNOS, inducible nitric oxide synthase; TGF-β, transforming growth factor-β; TLR, toll-like receptor; TNF-α, tumor necrosis factor-α. Macrophage-associated mechanisms in PDAC progression Macrophage-derived TNF-α has been demonstrated to facilitate the progression and proliferative activity of tumor cells. Tumor necrosis factor receptor 2 (TNFR2), a key binding receptor for TNF-α, is involved in mediating diverse cellular biological processes. Notably, a positive correlation has been observed between the expression levels of TNFR2 and those of programmed death ligand 1 (PD-L1), as TNFR2 modulates PD-L1 transcription via activation of the p65 NF-κB signaling cascade.51 Co-administration of anti-TNFR2 and anti-PD-L1 antibodies has been shown to induce robust anti-tumor immunity, while also promoting the formation of immunological memory for subsequent tumor surveillance. This combinatorial therapeutic strategy not only suppresses the infiltration of regulatory T cells (Tregs) and TAMs, but also reinforces the activation status of CD8+ T cells within the PDAC TME. The molecular mechanistic details underlying these enhanced immunotherapeutic effects first include that blocking TNFR2 directly restricts the malignant cell proliferative capacity by inactivating the NF-κB p65 pro-survival signaling axis. This thereby modulates key regulatory proteins, including c-Myc, cyclin D, and CDK2. Second, this intervention relieves immunosuppression within the tumor niche by reducing PD-L1 expression levels through the NF-κB p65/PD-L1 pathway, lowering the abundance of Tregs and TAMs while restoring the activity of dysfunctional T lymphocytes.51 Another key mediator is TNF-like weak inducer of apoptosis (TWEAK), which belongs to the TNF superfamily 12. M2 macrophages can trigger non-cell-autonomous TWEAK secretion through the CCL5/TRAF6/NF-κB (p65) signaling cascade. TWEAK drives skeletal muscle atrophy by activating MuRF1 via the Fn14/RELB/MuRF1 axis, thereby triggering muscle remodeling. Furthermore, tumor cells can recruit and reprogram macrophages through the CCL2/CCR2 signaling pathway, thus worsening cancer-related muscle wasting. Accordingly, interrupting the crosstalk between macrophages and tumor cells may represent a potential strategy to alleviate this pathological process.49 In malignancies, the colony-stimulating factor-1/CSF-1 receptor (CSF-1/CSF-1R) signaling axis supports TAM survival, expansion, and polarization in the TME. Preclinical investigations have revealed that agents targeting CSF-1R can eliminate TAM populations and strengthen the therapeutic activity of PD-1/PD-L1 immune checkpoint blockade across multiple cancer models, especially PDAC. This therapeutic strategy holds substantial promise for reversing tumor-mediated immunosuppression and elevating patient responsiveness to PD-1/PD-L1-targeted immunotherapy.49, 51, 52 Lysyl oxidase-like protein 2 (LOXL2) is associated with the epithelial-mesenchymal transition. TAMs can secrete oncostatin M to induce LOXL2 expression via the pSTAT3/SMAD3 pathway, which promotes PC growth and metastasis.53 Lastly, CD11b agonists can activate the STING/STAT/IFN-γ pathway in TAMs, enhancing anti-tumor T cell immunity while inducing p65 degradation to inhibit NF-κB/IL-1 signaling, thereby decelerating tumor progression. IFN-γ is essential for anti-tumor immunity and critical for inhibiting IL-1R signaling, further impeding PC development (Fig. 3).54Fig. 3Macrophage-driven immune regulation mechanisms and tumor dynamics in pancreatic cancer. (Created in BioRender. Long, Y [2026] https://BioRender.com/o69nihh).Abbreviations: Arg1, arginase 1; GARP, glycoprotein A repetitions predominant; GM-CSF, granulocyte-macrophage colony-stimulating factor; HLA-DR, histocompatibility complex II; IL, interleukin; iNOS, inducible nitric oxide synthase; PC, pancreatic cancer; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor. Macrophage-driven immune regulation mechanisms and tumor dynamics in pancreatic cancer. (Created in BioRender. Long, Y [2026] https://BioRender.com/o69nihh). Abbreviations: Arg1, arginase 1; GARP, glycoprotein A repetitions predominant; GM-CSF, granulocyte-macrophage colony-stimulating factor; HLA-DR, histocompatibility complex II; IL, interleukin; iNOS, inducible nitric oxide synthase; PC, pancreatic cancer; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor. Prostaglandin E2 (PGE2), secreted by PDAC cells, can induce macrophages to maintain an IL-1β+ TAM state. These TAMs in turn facilitate PDAC progression by secreting IL-1β, thereby forming a positive feedback loop between the PDAC cells and IL-1β-positive TAMs.55 Glycoprotein A repetitions predominant (GARP), a type I transmembrane protein serving as the receptor for latent TGF-β, binds to integrin αV/β8 complexes present on neoplastic cells, thereby modulating the crosstalk between M1 macrophages and PDAC cells.56 This interaction reprograms M1-like macrophages into M2-like macrophages, further promoting tumor growth and metastasis. Moreover, PDAC can trigger activation of the glucose-responsive gene IL-10 within macrophages via a DNA methylation-associated regulatory mechanism, thereby boosting macrophage migration activity through the IL-10/IL-10R signaling axis (Table 2).56Table 2Macrophage subtype roles and therapeutic mechanisms in pancreatic cancer.Table 2Macrophage subtypeMechanismKey Molecule/PathwayFunctionTherapeutic goalMethod/strategiesTherapeutic mechanismPotential outcomeReferencesM1-like TAMsAnti-tumor metastasisGARP, TGF-βPromote the conversion of M1 to M2, promoting tumor metastasisPromoting M1 PolarizationNeoadjuvant FOLFIRINOX chemotherapyIFN-γCD40 agonistAnti-PD-L1 antibodyGEM + Anti-PD-1 antibodyAdjust IRF4/IRF5 balanceEnhances M1 function, increases anti-tumor activity, inhibits M2 polarizationImproves anti-tumor immune microenvironmentInhibits tumor progression15,30,40,49,52,55,50M2-like TAMsEnhance anti-tumor immunityGARP, TGF-βEnhanced anti-tumor immune response by activating the STING/STAT/IFN-γ pathwayReducing M2 NumbersNeutralizing IL-4/IL-13STAT3 inhibitorsGARP blockersInhibiting miRNA-301α-3p and miRNA-193b-3pBlocking FGD5-AS1/STAT3/NF-kB pathwaysInhibits the generation of M2 and their immunosuppressive effectsReduces tumor immunosuppression Enhances anti-tumor immune responses28,35,47, 48, 49, 51,57,58Immunosuppression alleviatedTNFR2, PD-L1, NF-κB, p65Alleviate immunosuppression by blocking TNFR2 to downregulate PD-L1 expression.Tumor progression and metastasisPGE2, IL-1βMaintain the IL-1β+ TAM state, promoting tumor growthMuscle atrophyTWEAK, NF-κB, MuRF1Promote muscle atrophy and tumor progressionReprogramming M2RP-182KRAS G12D inhibitorsGalectin-9 blockadeDual inhibition of PI3K-γ and CSF-1/CSF-1RConverts M2 into M1Reduces tumor cell proliferationEnhances immune system activity18,34,39,45,47,54Proliferation and differentiation of TAMsCSF-1/CSF-1RPromote the proliferation and differentiation of TAMs through CSF-1/CSF-1R.EMTOSM, LOXL2, pSTAT3TAMs induce LOXL2 overexpression, promoting pancreatic cancer growth and metastasisAbbreviations: CSF-1R, colony stimulating factor 1 receptor; EMT, epithelial-mesenchymal transition; GARP, glycoprotein A repetitions predominant; GEM, gemcitabine; IFN-γ, interferon-γ; LOXL2, lysyl oxidase-like protein 2; OSM, oncostatin M; PD-L1, programmed cell death ligand 1; PGE2, prostaglandin E2; TAMs, tumor-associated macrophages; TGF-β, transforming growth factor-β; TNFR2, tumor necrosis factor receptor 2; TWEAK, TNF-like weak inducer of apoptosis. Table 2Macrophage subtype roles and therapeutic mechanisms in pancreatic cancer.Table 2Macrophage subtypeMechanismKey Molecule/PathwayFunctionTherapeutic goalMethod/strategiesTherapeutic mechanismPotential outcomeReferencesM1-like TAMsAnti-tumor metastasisGARP, TGF-βPromote the conversion of M1 to M2, promoting tumor metastasisPromoting M1 PolarizationNeoadjuvant FOLFIRINOX chemotherapyIFN-γCD40 agonistAnti-PD-L1 antibodyGEM + Anti-PD-1 antibodyAdjust IRF4/IRF5 balanceEnhances M1 function, increases anti-tumor activity, inhibits M2 polarizationImproves anti-tumor immune microenvironmentInhibits tumor progression15,30,40,49,52,55,50M2-like TAMsEnhance anti-tumor immunityGARP, TGF-βEnhanced anti-tumor immune response by activating the STING/STAT/IFN-γ pathwayReducing M2 NumbersNeutralizing IL-4/IL-13STAT3 inhibitorsGARP blockersInhibiting miRNA-301α-3p and miRNA-193b-3pBlocking FGD5-AS1/STAT3/NF-kB pathwaysInhibits the generation of M2 and their immunosuppressive effectsReduces tumor immunosuppression Enhances anti-tumor immune responses28,35,47, 48, 49, 51,57,58Immunosuppression alleviatedTNFR2, PD-L1, NF-κB, p65Alleviate immunosuppression by blocking TNFR2 to downregulate PD-L1 expression.Tumor progression and metastasisPGE2, IL-1βMaintain the IL-1β+ TAM state, promoting tumor growthMuscle atrophyTWEAK, NF-κB, MuRF1Promote muscle atrophy and tumor progressionReprogramming M2RP-182KRAS G12D inhibitorsGalectin-9 blockadeDual inhibition of PI3K-γ and CSF-1/CSF-1RConverts M2 into M1Reduces tumor cell proliferationEnhances immune system activity18,34,39,45,47,54Proliferation and differentiation of TAMsCSF-1/CSF-1RPromote the proliferation and differentiation of TAMs through CSF-1/CSF-1R.EMTOSM, LOXL2, pSTAT3TAMs induce LOXL2 overexpression, promoting pancreatic cancer growth and metastasisAbbreviations: CSF-1R, colony stimulating factor 1 receptor; EMT, epithelial-mesenchymal transition; GARP, glycoprotein A repetitions predominant; GEM, gemcitabine; IFN-γ, interferon-γ; LOXL2, lysyl oxidase-like protein 2; OSM, oncostatin M; PD-L1, programmed cell death ligand 1; PGE2, prostaglandin E2; TAMs, tumor-associated macrophages; TGF-β, transforming growth factor-β; TNFR2, tumor necrosis factor receptor 2; TWEAK, TNF-like weak inducer of apoptosis. Macrophage subtype roles and therapeutic mechanisms in pancreatic cancer. Abbreviations: CSF-1R, colony stimulating factor 1 receptor; EMT, epithelial-mesenchymal transition; GARP, glycoprotein A repetitions predominant; GEM, gemcitabine; IFN-γ, interferon-γ; LOXL2, lysyl oxidase-like protein 2; OSM, oncostatin M; PD-L1, programmed cell death ligand 1; PGE2, prostaglandin E2; TAMs, tumor-associated macrophages; TGF-β, transforming growth factor-β; TNFR2, tumor necrosis factor receptor 2; TWEAK, TNF-like weak inducer of apoptosis. Macrophage-related targeted therapies Therapeutic strategies to favor pro-inflammatory macrophage reprogramming In recent studies, neoadjuvant therapy has emerged as a prevalent treatment modality for PC. Research has indicated that neoadjuvant FOLFIRINOX chemotherapy can significantly alter the TME. Specifically, post-chemotherapy tumors have shown a six-fold increase in intraepithelial macrophage numbers, with a pronounced shift toward the M1 phenotype. Additionally, an increased distance between M2 macrophages and tumor cells compared with M1 macrophages has been observed, potentially indicating a favorable alteration of the tumor-immune landscape. This phenotypic shift toward M1-polarized macrophages following neoadjuvant FOLFIRINOX is likely attributable to both direct and indirect mechanisms.57,59 Chemotherapy agents, such as oxaliplatin, can induce immunogenic cell death of tumor cells, releasing DAMPs that may contribute to M1-skewing of macrophages.59,58 Concurrently, chemotherapy-mediated tumor debulking can remodel the hypoxic and immunosuppressive TME, creating a more permissive niche for M1 macrophage maintenance and function.57,60 However, the precise molecular pathways driving this repolarization remain to be fully elucidated. At present, this observation is mainly based on correlative pathological findings rather than direct mechanistic evidence. Given the previously observed correlation between M2 macrophage proximity and poorer clinical outcomes, these findings suggest that neoadjuvant FOLFIRINOX chemotherapy may improve treatment outcomes for PC patients.18 IFN-γ has been shown to effectively reprogram TAMs toward an M1-like phenotype.40 IFN-γ treatment in vitro can effectively polarize monocyte-derived macrophages toward the M1 phenotype, demonstrating promising anti-tumor activity in patients with advanced tumors. Within the TME, activated CD8+ T cells represent the primary source of IFN-γ. Clinically validated PD-1 inhibitors, such as pembrolizumab61 and nivolumab,50 can restore T cell function by blocking inhibitory signals, thereby enhancing IFN-γ production and subsequently promoting M1 macrophage polarization.62,63 Similarly, PD-L1 inhibitors, including atezolizumab,64 durvalumab, and avelumab, have been demonstrated to disrupt PD-L1/PD-1 interactions, relieving T cell suppression and augmenting IFN-γ release. This cascade further reinforces M1 macrophage polarization and enhances anti-tumor immunity, contributing to notable clinical efficacy across diverse cancer types.65 In PDAC, M2 macrophage polarization is coordinately regulated by IL-4 and IL-13. IL-4 is predominantly secreted by PSCs and tumor cells.15 Notably, PSCs also represent a major source of IL-13, a cytokine established as a key mediator of the M1-to-M2 phenotypic transition.38,66 Importantly, neutralization of IL-13 has been shown to markedly diminish the M2 macrophage population and suppress this phenotypic switch.40 Consequently, targeting both IL-4 and IL-13 released by PSCs has emerged as a promising therapeutic approach to diminish M2 macrophage accumulation and alleviate fibrosis in the pancreatic TME. Dupilumab,67, 68, 69 a fully human monoclonal antibody, intervenes in this pathway by specifically binding to the IL-4 receptor alpha subunit, thereby blocking the signaling of both cytokines and offering a viable means to impede M2 macrophage polarization.70,71 Furthermore, the PI3K-γ signaling cascade, alongside the CSF-1/CSF-1R axis, exerts pivotal regulatory effects, orchestrating the immunosuppressive microenvironment by primarily driving M2 macrophage recruitment and phenotypic polarization. Dysregulation of these pathways contributes to the development of a profoundly immunosuppressive tumor immune microenvironment in PC. Concurrently, inhibition of the PI3K-γ and CSF-1/CSF-1R pathways has been shown to reprogram M2-like macrophages into an M1-like phenotype.52,72 Selicrelumab is a fully human monoclonal antibody that selectively targets and activates CD40.73 Through agonism of CD40 signaling, this antibody can potentiate TNF-α production in in vitro co-culture systems. TNF-α, a cytokine associated with M1 macrophages, enhances the expression patterns of HLA-DR, while reducing those of CD163, in cancer tissues. This transition facilitates macrophage polarization toward the M1 functional phenotype, thereby suppressing PC cell malignant progression and invasive behavior. In a phase I neoadjuvant trial (NCT02588443) for resectable PDAC, selicrelumab combined with gemcitabine (GEM)/Nab-paclitaxel showed limited immediate radiographic tumor regression.74 Nevertheless, this combination effectively increased intratumoral M1-like TAMs and CD8+ T cell infiltration, with a subset of patients experiencing prolonged disease-free survival. These results suggested the potential for sustained anti-tumor immune remodeling despite limited immediate tumor regression.74,75 Additionally, these findings highlight both the promise and limitations of CD40 agonism as a single immunomodulatory intervention method in PC. Moreover, through direct intercellular communication, PC cells can selectively induce DNA methylation and downregulate a subset of glucose metabolism and oxidative phosphorylation-related genes in M1 macrophages, thereby impairing glucose metabolism in these cells.56 Within the PC TME, TAMs express PD-L1, contributing to T cell dysfunction and dampening T cell activation markers.40 Treatment with anti-PD-L1 agents can reprogram immunosuppressive TAMs and promote a shift in tumor vascularization toward a pro-inflammatory macrophage phenotype. Although GEM serves as a cornerstone chemotherapy for PC, its application as a monotherapy often results in tumor resistance.76 However, the combined administration of GEM and anti-PD-1 immune checkpoint antibodies has yielded synergistic anti-tumor effects, markedly elevating the intratumoral infiltration of Th1 lymphocytes and M1 macrophages. In a murine model of PC liver metastasis, mice receiving the GEM + anti-PD-1 antibody combination exhibited prolonged survival compared with those treated with GEM monotherapy.76 PC therapy targeting M2 macrophages Decreasing the number of M2 macrophages GARP mediates the phenotypic transition from M1-like macrophages to M2-like TAMs in PDAC. Therefore, inhibiting GARP may simultaneously preserve M1 polarization and reduce M2 macrophage accumulation.45,56 Driven by PC-derived exosomal FGD5-AS1, activation of the STAT3/NF-κB pathway in the TME can induce M2 macrophage polarization, thereby facilitating PC progression.43,77 Consequently, inhibiting STAT3 presents a potential therapeutic strategy for disrupting M2 macrophage development and restraining malignant progression. Ruxolitinib, an oral selective JAK1/2 inhibitor, targets the JAK2/STAT3 pathway to suppress STAT3 activation, impede cell growth and colony formation, and reduce inflammatory responses. Despite a robust preclinical rationale, the phase III JANUS 1 trial evaluating ruxolitinib in combination with capecitabine for metastatic PDAC failed to meet its primary endpoint of improved overall survival.78, 79, 80, 81, 82, 83 Post-hoc analyses indicated that patients with elevated systemic inflammation, as demonstrated by high C-reactive protein levels, might derive greater benefit. This implied that STAT3-targeted therapy may be preferentially effective in a molecularly defined subset of PC patients characterized by an inflammatory phenotype.84,85 Additionally, bortezomib can inhibit TNF-α release by suppressing NF-κB activation.86 Collectively, targeting these interconnected pathways offers promising diagnostic and therapeutic opportunities for PC. Exosomes, nanoscale vesicles involved in cell-to-cell communication, have emerged as critical mediators in tumor-stroma interactions.39,87 Recent studies have highlighted the role of tumor-derived exosomal miR-301α-3p in promoting M2 macrophage polarization through the PTEN/PI3K signaling pathway.88 This macrophage phenotypic shift creates a permissive microenvironment that enhances tumor cell motility, invasiveness, and metastatic competence, as well as supports the epithelial-mesenchymal transition. Targeting the PTEN/PI3K signaling axis, such as with the FDA-approved PI3K inhibitor alpelisib,89, 90, 91, 92 may offer a novel therapeutic approach in PC. Moreover, M2 macrophage-derived exosomal miR-193b-3p has been linked to enhanced PC cell proliferation, invasion, and immune suppression. Mechanistically, this miRNA promotes glutamine uptake, induces T cell depletion, and enhances tumor vascularization. Targeting miR-193b-3p or its downstream target, tripartite motif 62, which regulates tumor cell proliferation and migration, may therefore help decrease M2 macrophage activity and slow cancer progression.32,93 Further research has demonstrated that loss of the aromatic hydrocarbon receptor in TAMs results in reduced infiltration of these cells and diminished tumor burden in PDAC models.94 Another significant macrophage subset, CD163+ TAMs, is frequently found in malignant regions of the pancreas and is associated with advanced disease and poor prognosis. Reducing the number of these CD163+ macrophages in the TME could therefore potentially improve clinical outcomes.21,40 CSF-1 functions as a key myeloid growth factor that sustains macrophage lineage maintenance, expansion, and phenotypic maturation within the TME. PDAC cells actively release CSF-1 in the TME to attract CSF-1R-positive myeloid precursors and subsequently drive their differentiation toward immunosuppressive macrophage states, thereby promoting tumor growth and immune evasion.95,96 To counteract this mechanism, emactuzumab (RG7155), a humanized monoclonal antibody, specifically binds to CSF-1R on macrophages, blocking downstream CSF-1/CSF-1R signaling. Although emactuzumab has been clinically shown to effectively reduce the number of CD163+ TAMs in solid tumors,97 a phase Ib study evaluating emactuzumab plus the PD-L1 inhibitor atezolizumab in unselected advanced solid tumors (NCT02323191) did not demonstrate a clear synergistic benefit in the PC cohort.98,99 This outcome suggests that TAM depletion alone may be insufficient to overcome the profoundly immunosuppressive PDAC TME, emphasizing the necessity for combination partners that can simultaneously enhance effector T cell function.98,100 Furthermore, the small-molecule inhibitor pexidartinib (PLX3397) can inhibit the tyrosine kinase activity of CSF-1R, thereby disrupting this signaling axis. Pexidartinib has been approved for the treatment of tenosynovial giant-cell tumor, supporting the clinical relevance of targeting the CSF-1R pathway.101, 102, 103 A specific subset of TAMs, IL-1β+ TAMs, accumulates in hypoxic regions of tumors, triggering inflammatory reprogramming in the nearby cancer cells. Because targeting these IL-1β+ TAMs has been shown to slow tumor growth and boost cytotoxic T cell activity, this cell type has become a valuable target for therapeutic intervention. Upon exposure to PGE2 and TNF-α, tumor-infiltrating monocytes can differentiate into IL-1β+ TAMs, initiating an inflammatory reprogramming cascade in neighboring PDAC cells. Such cellular reprogramming can promote the production of PGE2, TNF-α, and multiple related inflammatory mediators, which in turn stabilize the pro-tumor phenotype of IL-1β+ TAMs and form a persistent positive feedback loop sustained by continuous TAM activation. Notably, the interactions between IL-1β+ TAMs and PDAC cell subpopulations exhibiting IL-1β response features are significantly correlated with reduced patient survival rates. Targeting IL-1β+ TAMs has been shown to result in delayed PDAC growth and heightened cytotoxic T cell activation, underscoring the therapeutic potential of reducing or functionally inhibiting this TAM subset.55 Reprogramming M2 macrophages in the TME Macrophage polarization is regulated by various transcription factors, notably interferon regulatory factor 4 (IRF4) and IRF5, which exhibit antagonistic functions. IRF4 drives M2 polarization by suppressing TLR signaling, contributing to tumor progression. By contrast, TLR agonists, such as poly(I: C), imiquimod (R837), and resiquimod (R848), can effectively stimulate macrophages to polarize toward an M1-like phenotype, enhancing anti-tumor immune responses.104, 105, 106 Consequently, TLR agonists are considered promising compounds for reprogramming TAMs and reversing their pro-tumor functions.104,107 Studies have demonstrated the potential use of these molecules as monotherapies for triggering anti-tumor immune responses.108, 109, 110 Although TLR agonists have advanced into clinical evaluation in several cancer types, their investigation in PC remains largely confined to preclinical models.104,107 Dedicated clinical trials are required to establish the safety, optimal dosing, and therapeutic efficacy of TLR-targeted agents in patients with PC.104 At the transcriptional level, IRF5 promotes M1 macrophage polarization, thereby enhancing anti-tumor immune responses.111 Regulating the dynamic equilibrium between this factor and its opposing transcriptional regulators can enable the phenotypic conversion of macrophages, switching them from a tumor-promoting M2 phenotype to an anti-tumor M1 phenotype.15 The endogenous defense regulator RP-182 induces a conformational change in CD206, a receptor on M2 macrophages, thereby enhancing their phagocytic, autophagic, and apoptotic activities. This transformation can effectively reprogram M2 macrophages into the anti-tumor M1 phenotype, presenting promising implications for cancer immunotherapy.34 Long non-coding RNAs differentially expressed between TAMs and normal TRMs in PDAC tissues were identified using RNA sequencing technology. Among these, SNHG-17 was found to be notably abundant in TAMs and exhibited a significant positive correlation with unfavorable clinical outcomes in patients with PDAC. Further functional investigations demonstrated that SNHG-17 contributes to the malignant development of PC by enhancing M2 macrophage polarization and accelerating anaerobic glycolysis in the TME.33 Strategies aimed at reducing SNHG-17 expression levels within TAMs hold promise for reversing M2 macrophage polarization and attenuating tumor progression. T cell immunoglobulin and mucin-domain containing protein 3 (TIM-3) is a critical inhibitory immune checkpoint molecule expressed on various innate immune cells, including macrophages, and plays a pivotal role in shaping the TME.112 Expression of galectin-9 (Gal-9), the TIM-3 ligand, is significantly upregulated in multiple cancer types, such as PDAC and PTEN-deficient glioblastoma (GBM), where it drives immunosuppression by modulating macrophage function.39 In different tumor contexts, Gal-9 engages distinct receptors to regulate macrophage polarization. In PDAC, it interacts with the innate immune receptor dectin-1 on macrophages, directly promoting their polarization toward an immunosuppressive M2 phenotype. In GBM, Gal-9-TIM-3 signaling activates downstream pathways that similarly skew macrophages toward an M2-like state.113 The engagement of Gal-9 with TIM-3 not only suppresses adaptive immunity, but also reinforces M2 macrophage polarization, collectively fostering an immune-tolerant microenvironment. Consequently, targeting the Gal-9/TIM-3 axis to reverse macrophage-mediated immunosuppression has emerged as a promising therapeutic strategy.114 Preclinical studies have demonstrated that blocking Gal-9 or TIM-3 can repolarize macrophages and restore T cell-mediated anti-tumor immunity. Accordingly, several TIM-3-targeting monoclonal antibodies, such as sabatolimab and the humanized cobolimab, are under active clinical investigation.115, 116, 117, 118 In particular, cobolimab has shown favorable tolerability in early-phase trials, supporting its further development as an immunomodulatory agent aimed at reprogramming TAMs.119 The KRAS G12D mutation, the most prevalent genetic alteration in PC, facilitates M2 macrophage polarization by modulating STAT3-dependent fatty acid oxidation. Preclinical investigations using mouse models have demonstrated that inhibiting KRAS G12D secretion and internalization within macrophages can effectively attenuate tumor progression, highlighting its promising value as a therapeutic target for the development of innovative anti-cancer strategies.120 Finally, spleen tyrosine kinase (SYK), which is specifically upregulated in human PDAC CD45+ immune cells compared with normal pancreatic cells, plays a crucial role in macrophage reprogramming toward an immunostimulating phenotype.121 Preclinical studies have demonstrated that combining the SYK small-molecule inhibitor R788 (fostamatinib) with Gem can synergistically suppress PDAC growth and metastasis.121,122 The mechanistic basis for this synergy is thought to be multifactorial: (1) R788 reprograms TAMs toward an immunostimulatory phenotype, thereby enhancing CD8+ T cell-mediated anti-tumor immunity;121 (2) Gem exerts direct cytotoxicity on tumor cells, simultaneously inducing macrophage polarization toward a pro-tumorigenic, immunosuppressive phenotype, which limits anti-tumor immune responses;121 (3) SYK inhibition may counteract Gem-induced immunosuppressive macrophage polarization, thereby potentiating the durability of the chemotherapeutic response.121 This complementary interplay between targeted immunomodulation and cytotoxic chemotherapy provides a strong rationale for clinically evaluating this combination in PDAC.121 These results establish SYK inhibition as a promising therapeutic strategy for PDAC.123 Entospletinib, a second-generation highly selective SYK inhibitor, was designed for more precise targeted inhibition. Early clinical data have also shown favorable safety and tolerability profiles, supporting its potential application in tumor immunotherapy combination regimens.124, 125, 126 Therapeutic prospects for targeting M2 macrophage subtypes Specific cytokines and influencing factors also mediate the mutual transformation between M2 macrophage subtypes. M2a macrophages express particular pattern recognition receptors, which enable them to detect and eliminate invading bacteria, fungi, and parasites, while their prominent feature is their ability to promote tissue remodeling. Following tissue injury, IL-4 release can induce macrophage differentiation into the M2a subtype. M2a macrophage-released IL-4 can further propagate macrophage polarization toward the M2a phenotype, thus amplifying IL-4 production and forming a positive feedback loop.35 Selective induction of chemokines, including CCL24, CCL17, and CCL22, by IL-4 and IL-13 in M2a macrophages has been observed, while IFN-γ can reduce their expression patterns. Additionally, CCL17, the CCR4 agonist, and IL-10 produced by M2a macrophages can suppress CPG-mediated M1 activation, thereby contributing to the immunomodulatory functions of this macrophage subtype.28 Previous research has identified inducible nitric oxide synthase as a representative molecular marker of pro-inflammatory M1 macrophages, while arginase 1 is widely recognized as a characteristic indicator of anti-inflammatory M2 macrophage subsets. The highest expression levels of nitric oxide synthase are detected in M1 macrophages, with significantly elevated levels observed in M2b macrophages compared with M2a and M2c macrophages. Conversely, M2b macrophages exhibit lower arginase 1 and IL-4 expression levels compared with M2a and M2c macrophages. Consequently, TAMs are deemed to possess characteristics resembling M2a and M2c macrophages, while M2b macrophages align more closely with the M1 phenotype. Nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 (NLRP3) acts as an inflammatory sensor protein. Co-culture of macrophages with PDAC cells led to NLRP3-mediated polarization toward M2a/c/d TAM-like phenotypes, while NLRP3 depletion induced M1/M2b polarization.43 Given the critical role of NLRP3 in immune regulation, the development of targeting strategies is particularly important. However, although the first-generation, highly selective inhibitor MCC950 is an important tool, its clinical development has been hindered by pharmacokinetic and safety issues.127, 128, 129 The subsequent generations of inhibitors, such as MCC7840 (inzomelid/emlenoflast) and DFV890, have shown improved properties, including better bioavailability, exposure, and half-life.130,131 In addition to directly inhibiting NLRP3, targeting its downstream IL-1 signaling pathway has also been clinically validated as an effective strategy. The IL-1R antagonist anakinra can indirectly inhibit NLRP3 function. Currently, the only clinically approved therapies targeting NLRP3-associated diseases are IL-1 pathway inhibitors, including canakinumab and anakinra.132,133 Notably, direct evidence for M2b macrophage-specific functions in PDAC remains limited.45,60 Certain TLR ligands, such as lipopolysaccharides, particularly in the presence of immune complexes, may promote an M2b-like phenotype.134,135 Evidence from macrophage biology studies has suggested that M2b macrophages secrete high levels of CCL1 to sustain their M2b properties, with CCL1 inhibition leading to their conversion into the M0 or M1 phenotype.135,136 However, there is a lack of direct validation in PDAC.45,60 (Table 3) Dexamethasone exerts inhibitory effects on M1 pro-inflammatory macrophages and promotes the polarization of M2c phenotype by modulating TGF-β signaling. The intensity of TGF-β signaling has emerged as a critical determinant of M2a and M2c macrophage differentiation. Accordingly, suitable TGF-β stimulation can facilitate the phenotypic polarization of M2c macrophages, while M2a macrophages undergo a mesenchymal-to-myoblast transition under the influence of TGF-β signaling.137Table 3Therapeutic strategies targeting tumor-associated macrophages in pancreatic cancer.Table 3Therapeutic Target/PathwayMechanismRepresentative DrugsDevelopment StageChallengesReferencesPD-1/PD-L1Blocking immune checkpoints and restoring the anti-tumor activity of T cellsPembrolizumab; Nivolumab; Atezolizumab; Durvalumab; AvelumabClinically approved (Multiple cancer types)Drug resistance; Immune-related adverse reactions54, 55, 56, 57, 58, 59, 60, 61IL-4/IL-13By binding to IL-4α, it inhibits IL-4 and IL-13 signaling and M2 macrophage polarization.DupilumabClinically approved (atopic dermatitis and asthma, etc.)Conjunctivitis; Adverse reactions at injection site62, 63, 64, 65, 66CD40Activate T cells and enhance anti-tumor immunitySelicrelumabPhase I/II clinical trials in PDACDrug toxicity; cytokine release syndrome; limited efficacy of single drug treatment68, 69, 70, 71JAK/STAT3/NF-kBInhibit inflammatory signaling pathways and regulate immunity and cell proliferationRuxolitinib; BortezomibClinically approved in non-PDAC malignancies; phase III trial negative in PDACDrug toxicity; mechanism unclear74, 75, 76, 77, 78, 79, 80, 81PI3KInhibit the PI3K signaling pathway and block the growth signals of tumor cellsAlpelisibClinically approved (Breast cancer)Drug toxicity; Drug resistance84, 85, 86, 87CSF-1/CSF-1RInhibit the formation of M2 type macrophages and improve the tumor microenvironmentPexidartinib; EmactuzumabPartial clinical approved (tenosynovial giant cell tumor)Hepatotoxicity; Multi target inhibition; Unclear biomarkers92,94, 95, 96TLRPromote M1-like macrophage polarization and enhance innate immune activationPoly(I:C); Imiquimod(R837); Resiquimod(R848)Preclinical stage in PDAC (clinically approved in non-PDAC indications)Drug toxicity; Limited efficacy of single drug; Unclear mechanism; Difficult clinical application; Individualized differences97, 98, 99, 100, 101, 102, 103, 104Gal-9/TIM-3Block TIM-3-mediated T cell exhaustion and restore immune functionSabatolimab; CobolimabUndergoing clinical developmentDrug toxicity; Limited efficacy of single drug; Efficacy is affected by tumor type106, 107, 108, 109, 110, 111, 112SykReprogram immunosuppressive TAMs and enhance chemotherapy sensitivityFostamatinib; EntospletinibPreclinical stage in PDAC (clinically approved for non-oncologic indications)Drug adverse reactions; Individual variability; Difficulties in clinical conversion116, 117, 118, 119, 120NLRP3Inhibit the activation of inflammasomes and alleviate the inflammatory responseDFV890; Anakinra; Canakinumab; MCC950; InzomelidPreclinical stage in PDACDrug toxicity; poor pharmacokinetics; difficult clinical conversion121, 122, 123, 124, 125, 126, 127Abbreviations: CSF-1, colony stimulating factor 1; CSF-1R, colony stimulating factor 1 receptor; Gal-9, galectin-9; IL, interleukin; NLRP3, nucleotide-binding oligomerization domain (NOD)-like receptor protein 3; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PI3k, phosphatidylinositol 3-kinase; TIM-3, T cell immunoglobulin and mucin-domain containing protein 3; TLR, toll-like recept. Table 3Therapeutic strategies targeting tumor-associated macrophages in pancreatic cancer.Table 3Therapeutic Target/PathwayMechanismRepresentative DrugsDevelopment StageChallengesReferencesPD-1/PD-L1Blocking immune checkpoints and restoring the anti-tumor activity of T cellsPembrolizumab; Nivolumab; Atezolizumab; Durvalumab; AvelumabClinically approved (Multiple cancer types)Drug resistance; Immune-related adverse reactions54, 55, 56, 57, 58, 59, 60, 61IL-4/IL-13By binding to IL-4α, it inhibits IL-4 and IL-13 signaling and M2 macrophage polarization.DupilumabClinically approved (atopic dermatitis and asthma, etc.)Conjunctivitis; Adverse reactions at injection site62, 63, 64, 65, 66CD40Activate T cells and enhance anti-tumor immunitySelicrelumabPhase I/II clinical trials in PDACDrug toxicity; cytokine release syndrome; limited efficacy of single drug treatment68, 69, 70, 71JAK/STAT3/NF-kBInhibit inflammatory signaling pathways and regulate immunity and cell proliferationRuxolitinib; BortezomibClinically approved in non-PDAC malignancies; phase III trial negative in PDACDrug toxicity; mechanism unclear74, 75, 76, 77, 78, 79, 80, 81PI3KInhibit the PI3K signaling pathway and block the growth signals of tumor cellsAlpelisibClinically approved (Breast cancer)Drug toxicity; Drug resistance84, 85, 86, 87CSF-1/CSF-1RInhibit the formation of M2 type macrophages and improve the tumor microenvironmentPexidartinib; EmactuzumabPartial clinical approved (tenosynovial giant cell tumor)Hepatotoxicity; Multi target inhibition; Unclear biomarkers92,94, 95, 96TLRPromote M1-like macrophage polarization and enhance innate immune activationPoly(I:C); Imiquimod(R837); Resiquimod(R848)Preclinical stage in PDAC (clinically approved in non-PDAC indications)Drug toxicity; Limited efficacy of single drug; Unclear mechanism; Difficult clinical application; Individualized differences97, 98, 99, 100, 101, 102, 103, 104Gal-9/TIM-3Block TIM-3-mediated T cell exhaustion and restore immune functionSabatolimab; CobolimabUndergoing clinical developmentDrug toxicity; Limited efficacy of single drug; Efficacy is affected by tumor type106, 107, 108, 109, 110, 111, 112SykReprogram immunosuppressive TAMs and enhance chemotherapy sensitivityFostamatinib; EntospletinibPreclinical stage in PDAC (clinically approved for non-oncologic indications)Drug adverse reactions; Individual variability; Difficulties in clinical conversion116, 117, 118, 119, 120NLRP3Inhibit the activation of inflammasomes and alleviate the inflammatory responseDFV890; Anakinra; Canakinumab; MCC950; InzomelidPreclinical stage in PDACDrug toxicity; poor pharmacokinetics; difficult clinical conversion121, 122, 123, 124, 125, 126, 127Abbreviations: CSF-1, colony stimulating factor 1; CSF-1R, colony stimulating factor 1 receptor; Gal-9, galectin-9; IL, interleukin; NLRP3, nucleotide-binding oligomerization domain (NOD)-like receptor protein 3; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PI3k, phosphatidylinositol 3-kinase; TIM-3, T cell immunoglobulin and mucin-domain containing protein 3; TLR, toll-like recept. Therapeutic strategies targeting tumor-associated macrophages in pancreatic cancer. Abbreviations: CSF-1, colony stimulating factor 1; CSF-1R, colony stimulating factor 1 receptor; Gal-9, galectin-9; IL, interleukin; NLRP3, nucleotide-binding oligomerization domain (NOD)-like receptor protein 3; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PI3k, phosphatidylinositol 3-kinase; TIM-3, T cell immunoglobulin and mucin-domain containing protein 3; TLR, toll-like recept. Challenges and future perspectives in clinical translation Despite promising preclinical advances, the clinical translation of TAM-targeted therapies for PC faces considerable obstacles.100,138 One major challenge is target specificity and off-tumor toxicity. For example, although CSF-1R inhibitors, such as pexidartinib, can effectively deplete TAMs, they also disrupt TRMs in the liver (Kupffer cells) and bone (osteoclasts), leading to dose-limiting adverse events, including hepatotoxicity, fatigue, and periorbital edema.139,140 Furthermore, TME plasticity can drive adaptive resistance. Blockade of the CSF-1/CSF-1R axis may trigger the compensatory recruitment of MDSCs or Tregs via alternative chemokine pathways, such as CXCL2 and CCL2, thereby blunting therapeutic efficacy.141,142 Another critical barrier is the lack of validated predictive biomarkers.143 It remains unclear which patients are most likely to benefit from TAM-reprogramming strategies, underscoring the need for biomarker-driven patient stratification in future trials.143 Finally, PDAC has a uniquely dense and hypovascular fibrotic stroma, which imposes physical barriers that limit the intratumoral penetration of monoclonal antibodies and immune effector cells. This could potentially explain the observed modest activity of TAM-targeted agents when administered as monotherapies.138,144 Overcoming these hurdles will require rationally designed combination regimens, refined patient selection, and the development of next-generation therapeutics with improved tumor specificity. Conclusions Macrophages are central orchestrators of PC progression, largely through their dynamic interactions with stromal and immune components that collectively shape an immunosuppressive TME and support malignant expansion. Within PDAC lesions, TAMs are continuously influenced by neoplastic cells to acquire phenotypes that reinforce local invasion, stromal remodeling, and metastatic dissemination. Key signaling pathways, such as TNF-α/TNFR2 and CSF-1/CSF-1R, help TAMs survive and proliferate, while contributing to immunosuppression. Targeting these pathways with therapies like anti-TNFR2, anti-PD-L1, and CSF-1R inhibitors has shown promise in reducing TAMs and enhancing immune responses. Additionally, macrophages contribute to cancer-related muscle wasting and metastasis, making them a significant therapeutic target for improving treatment outcomes in PC. CRediT authorship contribution statement Yuxi Long: Writing – original draft, Data curation, Conceptualization. Luoyingzi Xie: Writing – original draft, Data curation, Conceptualization. Fuming Xie: Writing – original draft, Data curation, Conceptualization. Xianxing Wang: Writing – original draft, Data curation. Huaizhi Wang: Writing – review & editing. Tian Yang: Writing – review & editing. Lei Cai: Writing – review & editing, Writing – original draft, Data curation, Conceptualization. Informed consent Not applicable. Ethics statement Not applicable. Organ donation Not applicable. Animal treatment Not applicable. Data availability statement Data sharing is not applicable to this article as no datasets were generated or analysed. Declaration of generative AI and AI-assisted technologies in the writing process The author(s) declare that no generative AI or AI-assisted technologies were used in the preparation of this manuscript. Funding This work was supported by grants from National Natural Science Foundation of China (No.82573500, PI: L.C.), Chongqing Overseas Chinese Returned Entrepreneurship and Innovation Foundation (cx2022041, PI: L.C.), Chongqing Natural Science Foundation (CSTB2022NSCQ-MSX1460, PI: L.C.). Conflicts of interest Lei Cai serves as Executive Assistant Editor and Tian Yang as Executive Editor-in-Chief of this journal. Neither was involved in the peer review or editorial decision-making for this article. The other author declare no conflicts of interest.